Published in Semin Oncol on December 01, 2002
Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Res (2005) 3.01
Acidity generated by the tumor microenvironment drives local invasion. Cancer Res (2013) 2.63
High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish. Proc Natl Acad Sci U S A (2007) 2.13
Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res (2006) 1.56
The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex-interactive agents. Mol Cancer Ther (2008) 1.44
Increased perfusion in normal appearing white matter in high inflammatory multiple sclerosis patients. PLoS One (2015) 1.41
Natural products and colon cancer: current status and future prospects. Drug Dev Res (2008) 1.34
Imaging cycling tumor hypoxia. Cancer Res (2010) 1.32
Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol (2009) 1.27
Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology (2008) 1.17
Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphat Res Biol (2008) 1.16
The antivascular action of physiotherapy ultrasound on a murine tumor: role of a microbubble contrast agent. Ultrasound Med Biol (2007) 1.12
Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia (2008) 1.08
Evidence of the formation of G-quadruplex structures in the promoter region of the human vascular endothelial growth factor gene. Nucleic Acids Res (2010) 1.04
The antivascular action of physiotherapy ultrasound on murine tumors. Ultrasound Med Biol (2005) 1.02
Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.02
Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy. J Ultrasound Med (2012) 1.01
N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. Am J Pathol (2004) 0.99
Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation. BMC Gastroenterol (2010) 0.97
Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis (2010) 0.95
The disruption of murine tumor neovasculature by low-intensity ultrasound-comparison between 1- and 3-MHz sonication frequencies. Acad Radiol (2008) 0.93
Scutellaria barbata D. Don inhibits tumor angiogenesis via suppression of Hedgehog pathway in a mouse model of colorectal cancer. Int J Mol Sci (2012) 0.93
Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem (2011) 0.93
Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. Ann Surg Oncol (2014) 0.90
Solution structure of the major G-quadruplex formed in the human VEGF promoter in K+: insights into loop interactions of the parallel G-quadruplexes. Nucleic Acids Res (2013) 0.90
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs (2011) 0.90
Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. Nucleic Acids Res (2013) 0.90
Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α. Int J Cancer (2012) 0.89
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat (2016) 0.88
Advanced targeted nanomedicine. J Biotechnol (2015) 0.87
Molecule action mechanisms of NM-3 on human gastric cancer SGC-7901 cells in vivo or in vitro. World J Gastroenterol (2003) 0.87
Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol (2015) 0.87
Arginine dependence of tumor cells: targeting a chink in cancer's armor. Oncogene (2016) 0.86
Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool. Transl Oncol (2011) 0.84
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics (2008) 0.84
Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings. Transl Gastrointest Cancer (2012) 0.83
Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem (2008) 0.83
Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. J Gastroenterol (2008) 0.82
Molecular imaging agents: impact on diagnosis and therapeutics in oncology. Expert Rev Mol Med (2010) 0.82
The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer (2013) 0.82
Loading of VEGF to the heparin cross-linked demineralized bone matrix improves vascularization of the scaffold. J Mater Sci Mater Med (2009) 0.82
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. Cancer Biol Ther (2014) 0.80
Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model. Diabetes Metab J (2011) 0.80
The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines. Bioorg Med Chem Lett (2010) 0.79
In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models. Eur J Nucl Med Mol Imaging (2012) 0.79
Antiangiogenic therapy in human gastrointestinal malignancies. Gut (2006) 0.79
Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. Proc Natl Acad Sci U S A (2015) 0.78
A hybrid model of the role of VEGF binding in endothelial cell migration and capillary formation. Front Oncol (2013) 0.78
Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model. Med Sci Monit (2015) 0.78
Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol (2006) 0.78
Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery. Mol Imaging Biol (2016) 0.77
In vitro footprinting of promoter regions within supercoiled plasmid DNA. Methods Mol Biol (2010) 0.76
Biological response modifiers in cancer. MedGenMed (2006) 0.76
Dual Functional Mesoporous Silicon Nanoparticles Enhance the Radiosensitivity of VPA in Glioblastoma. Transl Oncol (2017) 0.75
Rapid in vitro derivation of endothelium directly from human cancer cells. PLoS One (2013) 0.75
Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies. Breast Care (Basel) (2009) 0.75
Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma. J Vis Exp (2014) 0.75